Tue, 03 Aug 2021

NEW YORK CITY, New York: Drugmaker Bristol-Myers Squibb has entered into a collaboration agreement worth up to $3.10 billion with Japan's Eisai to develop and market an experimental cancer drug in Asia, Europe, the United States and Canada.

Eisai is developing an antibody drug called MORAb-202 to treat solid tumors, including ovarian, lung and breast cancers. The drug is in the early stages of development.

Under the agreement, Bristol-Myers will pay $650 million, including for research and development expenses, to Eisai, Reuters reported.

Eisai will also be entitled to $2.45 billion in milestone payments and receive a royalty from Bristol-Myers on sales outside specific territories.

Earlier in May, Bristol-Myers signed an exclusive $1.56-billion deal with Agenus to develop and commercialize an experimental drug for treating immuno-oncology conditions, such as non-small-cell lung cancer.

More Tokyo News

Access More

Sign up for The Tokyo News

a daily newsletter full of things to discuss over drinks.and the great thing is that it's on the house!